Maybe not Daddy Warbucks, but the Celgene/Agios acute myeloid leukemia drug (IDHIFA, AG-221) has a lot going for it. The drug: passed priority FDA review after just Phase I/II data; uses Abbott’s RealTime™ IDH2 companion diagnostic test; was approved weeks ahead of the PDUFA date; has an orphan designation; oh, and it has a monthly wholesale acquisition cost of $24,872. Also, if you had invested in Agios six months ago, your investment would have retuned ~42%. Not too shabby. This is good news for Celgene and Agios, but it is also potentially great news for people who suffer from acute myeloid leukemia with the IDH2 mutation. Here is an infographic on AML. The next step? Let’s see what payer formularies say about the price.